Wockhardt represents a unique low risk high gain potential investment in the Indian Pharma space. It is quite amazing to notice that Wockhardt (CMP RS 865) which is one of the top 10 pharma companies by profits and having one of the highest Return on equity should be quoting at such abysmal valuations. In comparison to its peers it is quoting at nearly 40-50% discount making it a low risk investment.

Given the fact that its turnover is over Rs 5000 crore and has enviable margins of +30%, its only time that the market starts re-rating this stock. On the basis of our conservative estimates we would expect the stock to rally and cover the valuation gap with its peers implying a nearly 70-100% appreciation from current levels over the next 12-18 months.

Further we would not be surprised if Wockhardt were to sharply surprise to the upside on its performance beating our own estimates.

http://bit.ly/MFyqlD

Glenn Neely examines several social manias including d current "end-of-world" predictions linked 2 d "end" of d Mayan calendar. Mr. Neely offers specific mkt predictions 4 2012.

http://www.neowave.com/company-interview-may2012.asp

Raw wool (13.15%) castor seed (13.15%) & CWO (13.05%) gace d best yields in NSEL. Addnl info

http://on.fb.me/Mc0X1N

http://bit.ly/M6Iq3D